Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice

被引：3

作者：

Rossi, Luigi ^{[1
,2
]}

Veltri, Enzo ^{[1
]}

Zullo, Angelo ^{[3
]}

Zoratto, Federica ^{[1
,2
]}

Colonna, Maria ^{[4
]}

Di Seri, Marisa ^{[5
]}

Longo, Flavia ^{[5
]}

Mottolese, Marcella ^{[6
]}

Giannarelli, Diana ^{[7
]}

Ruco, Luigi ^{[8
]}

Romiti, Adriana

Barucca, Viola

Adua, Daniela ^{[5
]}

Tomao, Silverio ^{[1
,2
]}

机构：

[1] SM Goretti Hosp, Latina, Italy

[2] Univ Roma La Sapienza, Rome, Italy

[3] Nuovo Regina Margherita Hosp, Rome, Italy

[4] Di Liegro Hosp, Latina, Italy

[5] Univ Roma La Sapienza, Policlin Umberto I Hosp, Rome, Italy

[6] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy

[7] Regina Elena Inst Canc Res, Biostat Sci Direct, Rome, Italy

[8] Univ Roma La Sapienza, St Andrea Hosp, Dept Pathol, Rome, Italy

来源：

FUTURE ONCOLOGY | 2012年 / 8卷 / 09期

关键词：

bevacizumab; KRAS; liver metastases; metastatic colorectal cancer; VEGF; 1ST-LINE TREATMENT; PHASE-III; K-RAS; MUTATION STATUS; FLUOROURACIL; LEUCOVORIN; CAPECITABINE; OXALIPLATIN; COMBINATION; IRINOTECAN;

D O I：

10.2217/FON.12.108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The effect of KRAS status on response to bevacizumab plus chemotherapy in metastatic colorectal cancer is still unclear. We aimed to evaluate the overall clinical response to such a therapy in clinical practice and assess the role of KRAS status on therapy response. Patients & methods: This was a retrospective study enrolling 108 metastatic colorectal cancer patients. KRAS mutation analysis was performed by PCR. Results: Overall, 41.7% of patients had stable disease, 39.8% a partial response, 3.7% a complete response and 14.8% disease progression. Both clinical benefit and objective response rate tended to be higher in patients with only hepatic metastases than those with extrahepatic or multiple metastases. Response to therapy would appear to be independent of KRAS status, but larger studies are needed. Conclusion: Bevacizumab plus chemotherapy provides clinical benefit and objective response rate in patients with metastatic colorectal cancer independently of KRAS expression, especially in those patients with only liver metastases.

引用

页码：1193 / 1197

页数：5

共 50 条

[41] Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, Jolien
Koopman, Miriam
Cats, Annemieke
Rodenburg, Cees J.
Creemers, Geert J. M.
Schrama, Jolanda G.
Erdkamp, Frans L. G.
Vos, Allert H.
van Groeningen, Cees J.
Sinnige, Harm A. M.
Richel, Dirk J.
Voest, Emile E.
Dijkstra, Jeroen R.
Vink-Borger, Marianne E.
Antonini, Ninja F.
Mol, Linda
van Krieken, Johan H. J. M.
Dalesio, Otilia
Punt, Cornelis J. A.
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06): : 563 - 572
[42] Chemotherapy With Bevacizumab for Advanced or Metastatic Colorectal Cancer
Hirata, Masaru
GASTROENTEROLOGY, 2014, 146 (05) : S694 - S694
[43] Sex as a predictive factor in metastatic colorectal cancer treated with bevacizumab containing chemotherapy
Jeong, Jae-Heon
Baek, Sun Kyung
Chae, Jung Min
Lee, Gil Yeon
Park, Sun Jin
Kim, Si-Young
Yoon, Hwi Joong
Cho, Kyung Sam
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[44] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
Andre, Thierry
Jose Maria, Vieitez
Bouche, Olivier
Bennouna, Jaafar
Sastre, Javier
Alonso-Orduna, Vicente
Arnold, Dirk
Osterlund, Pia
Greil, Richard
Van Cutsem, Eric
von Moos, Roger
Reyes-Rivera, Irmarie
Makrutzki, Martina
Kubicka, Stefan
ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
[45] CHOICE OF CETUXIMAB-CONTAINING CHEMOTHERAPY IN PRE-TREATED METASTATIC COLORECTAL CANCER PATIENTS IN CLINICAL PRACTICE
Bruera, G.
Cannita, K.
Santomaggio, A.
Tudini, M.
Baldi, Lanfiuti P.
Mancini, M.
Spagnuolo, M.
Ricevuto, E.
Ficorella, C.
ANNALS OF ONCOLOGY, 2009, 20
[46] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
Di Fiore, F.
Blanchard, F.
Charbonnier, F.
Le Pessot, F.
Lamy, A.
Galais, M. P.
Bastit, L.
Killian, A.
Sesboue, R.
Tuech, J. J.
Queuniet, A. M.
Paillot, B.
Sabourin, J. C.
Michot, F.
Michel, P.
Frebourg, T.
BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1166 - 1169
[47] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F Di Fiore
F Blanchard
F Charbonnier
F Le Pessot
A Lamy
M P Galais
L Bastit
A Killian
R Sesboüé
J J Tuech
A M Queuniet
B Paillot
J C Sabourin
F Michot
P Michel
T Frebourg
British Journal of Cancer, 2007, 96 : 1166 - 1169
[48] Clinical relevance of kras mutation detection in metastatic colorectal cancer treated by cetuximala plus chemotherapy
Di fiore, Frederic
Le pessot, Florence
Blanchard, France
Charbonnier, Francoise
Lamy, Aude
Frebourg, Thierry
Michel, Pierre
GASTROENTEROLOGY, 2007, 132 (04) : A433 - A433
[49] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Kotani, D.
Kuboki, Y.
Yasuda, K.
Nakamura, Y.
Kawazoe, A.
Bando, H.
Taniguchi, H.
Shitara, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
[50] Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
Malka, D.
Boige, V.
Jacques, N.
Vimond, N.
Adenis, A.
Boucher, E.
Pierga, J. Y.
Conroy, T.
Chauffert, B.
Francois, E.
Guichard, P.
Galais, M. P.
Cvitkovic, F.
Ducreux, M.
Farace, F.
ANNALS OF ONCOLOGY, 2012, 23 (04) : 919 - U5

← 1 2 3 4 5 →